Table 1.
Patient population.
| Characteristic | Total (n = 1088) |
Initially observed (n = 461) |
Initially treated (n = 617) |
Diagnostic and therapeutic surgery (n = 10) |
Required treatment (n = 924) |
|
|---|---|---|---|---|---|---|
| Median age (range), years | 57 (20–94) | 57 (22–88) | 57 (20–94) | 67 (47–81) | 57 (20–94) | |
| Sex | Female | 550 (51) | 244 (53) | 302 (49) | 4 (40) | 452 (49) |
| Male | 538 (49) | 217 (47) | 315 (51) | 6 (60) | 472 (51) | |
| FLIPI at diagnosis | High | 255 (23) | 73 (16) | 181 (29) | 1 (10) | 235 (25) |
| Intermediate | 259 (24) | 126 (27) | 131 (21) | 2 (20) | 229 (25) | |
| Low | 337 (31) | 148 (32) | 184 (30) | 5 (50) | 266 (29) | |
| Unknown | 237 (22) | 114 (25) | 121 (20) | 2 (20) | 194 (21) | |
| Stage at diagnosis | I | 199 (18) | 51 (11) | 140 (23) | 8 (80) | 171 (19) |
| II | 142 (13) | 80 (17) | 60 (10) | 2 (20) | 102 (11) | |
| III | 317 (29) | 168 (36) | 149 (24) | 0 (0) | 270 (29) | |
| IV | 420 (39) | 154 (33) | 266 (43) | 0 (0) | 372 (40) | |
| Unknown | 10 (1) | 8 (2) | 2 (<1) | 0 (0) | 9 (1) | |
| Hemoglobin, g/dl | ≥12 | 829 (76) | 373 (81) | 450 (73) | 6 (60) | 697 (75) |
| <12 | 114 (10) | 26 (6) | 85 (14) | 3 (30) | 101 (11) | |
| Unknown | 145 (13) | 62 (13) | 82 (13) | 1 (10) | 126 (14) | |
| Nodal area, cm2 | ≤4 | 666 (61) | 289 (63) | 367 (59) | 10 (100) | 541 (59) |
| >4 | 404 (37) | 160 (35) | 244 (40) | 0 (0) | 365 (40) | |
| Unknown | 18 (2) | 12 (3) | 6 (1) | 0 (0) | 18 (2) | |
| LDH, U/L | Normal | 620 (57) | 276 (60) | 338 (55) | 6 (60) | 525 (57) |
| Elevated | 162 (15) | 40 (9) | 121 (20) | 1 (10) | 149 (16) | |
| Unknown | 306 (28) | 145 (31) | 158 (26) | 3 (30) | 250 (27) | |
| Bone marrow | Negative | 528 (49) | 182 (39) | 339 (55) | 7 (70) | 462 (50) |
| Positive | 327 (30) | 129 (28) | 198 (32) | 0 (0) | 293 (32) | |
| Unknown | 233 (21) | 150 (33) | 80 (13) | 3 (30) | 169 (18) | |
| PET staged | No | 403 (37) | 176 (38) | 223 (36) | 4 (40) | 350 (38) |
| Yes | 652 (60) | 269 (58) | 378 (61) | 5 (50) | 542 (59) | |
| Unknown | 33 (3) | 16 (3) | 16 (3) | 1 (10) | 32 (3) | |
| Anthracycline exposure at any time | No | 424 (39) | 220 (48) | 195 (32) | 9 (90) | 314 (34) |
| Yes | 468 (43) | 140 (30) | 327 (53) | 1 (10) | 467 (51) | |
| Unknown | 196 (18) | 101 (22) | 95 (15) | 0 (0) | 143 (15) | |
| Rituximab exposure at any time | No | 193 (18) | 20 (4) | 164 (27) | 9 (90) | 185 (20) |
| Yes | 739 (68) | 285 (62) | 453 (73) | 1 (10) | 739 (80) | |
| Unknown | 156 (14) | 156 (34) | 0 (0) | 0 (0) | 0 (0) |
Data are n (%).